Detalhe da pesquisa
1.
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.
Invest New Drugs
; 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38483782
2.
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Invest New Drugs
; 42(1): 145-159, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38324085
3.
Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.
Invest New Drugs
; 41(3): 380-390, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37040046
4.
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Invest New Drugs
; 2024 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38767685
5.
A Population Pharmacokinetic Assessment of the Effect of Food on Selumetinib in Patients with Neurofibromatosis Type 1-Related Plexiform Neurofibromas and Healthy Volunteers.
Clin Pharmacol Drug Dev
; 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38591154
6.
A physiologically based pharmacokinetic model for V937 oncolytic virus in mice.
Front Pharmacol
; 14: 1211452, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37771727
7.
Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based Modeling.
Clin Pharmacol Ther
; 114(3): 623-632, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37170933
8.
Aristolochic acid I metabolism in the isolated perfused rat kidney.
Chem Res Toxicol
; 25(1): 130-9, 2012 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-22118289
9.
Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens.
J Clin Pharmacol
; 61(11): 1493-1504, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34196005
10.
Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration.
Front Pharmacol
; 12: 705443, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34366859
11.
Pivotal Dose of Pembrolizumab: A Dose-Finding Strategy for Immuno-Oncology.
Clin Pharmacol Ther
; 110(1): 200-209, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33462831
12.
Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
Cancer Chemother Pharmacol
; 88(2): 189-202, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33903938
13.
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer.
Clin Cancer Res
; 26(18): 4767-4776, 2020 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32611648
14.
Systematic Literature Review and Meta-Analysis of Response to First-Line Therapies for Advanced/Metastatic Urothelial Cancer Patients Who Are Cisplatin Ineligible.
Am J Clin Oncol
; 42(10): 802-809, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31503064
15.
Immunogenicity of pembrolizumab in patients with advanced tumors.
J Immunother Cancer
; 7(1): 212, 2019 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31395089
16.
Evaluation of dosing strategy for pembrolizumab for oncology indications.
J Immunother Cancer
; 5: 43, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28515943
17.
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
J Clin Oncol
; 34(36): 4354-4361, 2016 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27998224
18.
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.
J Clin Oncol
; 34(36): 4371-4380, 2016 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27601554
19.
Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.
J Clin Oncol
; 33(30): 3409-15, 2015 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25964244
20.
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
J Clin Oncol
; 33(9): 1060-6, 2015 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25605849